BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Regenicin, Inc. Clears Past Due Payment to Lonza Walkersville, Inc.


6/21/2011 7:45:05 AM

LITTLE FALLS, NJ--(Marketwire - June 21, 2011) - Regenicin, Inc. (OTCBB: RGIN), a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, recently announced it has reimbursed Lonza Walkersville, Inc. for their work in moving Regenicin's leading product candidate through the FDA application process. The total payment to Lonza Walkersville, Inc. was in the amount of $260,344.23.

On April 20, 2011, Regenicin received a letter from Lonza America Inc. alleging the company was in breach of its Know-How License and Stock Purchase Agreement with Lonza Walkersville, Inc. That letter identified a past due payment of $183,687, which was later increased to $260,344.23 as reflected in a letter Regenicin received from Lonza dated June 1, 2011.

While there was a dispute in the amount owed under the Agreement, in order to avoid a conflict with an important contractual partner in the pursuit of its business objectives, Regenicin paid Lonza the invoices claimed in full. "We look forward to a long and successful relationship in the future with the Lonza team," said Randall McCoy, Regenicin's CEO, "and we're happy to have this issue behind us as we move forward."

About Regenicin
Regenicin, Inc. (OTCBB: RGIN), is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs.

Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New Jersey.

Safe Harbor Statement. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Allison Van Ness
646-403-3581
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES